Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma

Lymphoma Clinical Trial

Official title:

A Multi-Centre Phase II Trial Investigating the Efficacy and Tolerability of Bortezomib Added to Cyclophosphamide, Vincristine, Prednisone, and Rituximab (BCVP-R) for Patients With Advanced Stage Follicular Non-Hodgkin's Lymphoma Requiring Systemic First-Line Treatment

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00428142
• Other study ID #: LY13
• Secondary ID: CAN-NCIC-LY13CDR
• Status: Completed
• Phase: Phase 2
• Start date: May 1, 2007
• Est. completion date: January 6, 2012

Study information

• Verified date: November 2012
• Source: Canadian Cancer Trials Group
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide, vincristine, and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving bortezomib together with combination chemotherapy and rituximab may kill more cancer cells.

PURPOSE: This phase II trial is studying the side effects and how well giving bortezomib together with combination chemotherapy and rituximab works when given as first-line therapy in treating patients with stage III or stage IV follicular non-Hodgkin's lymphoma.

Description:

OBJECTIVES:

Primary

• Assess the efficacy of systemic first-line treatment comprising bortezomib, cyclophosphamide, vincristine, prednisone, and rituximab, in terms of complete response rate, in patients with stage III or IV follicular non-Hodgkin's lymphoma.

• Assess the incidence of severe neurotoxicity (defined as grade 3 or 4 neuropathy or neuropathic pain during the first 4 courses of treatment) in patients treated with this regimen.

Secondary

• Assess the overall response rate and response duration in patients treated with this regimen.

• Determine progression-free and overall survival of patients treated with this regimen.

• Evaluate the tolerability and characterize the toxicity profile of this regimen in these patients.

• Assess quality of life, with particular focus on neurotoxicity-related changes, of patients treated with this regimen.

OUTLINE: This is a multicenter, nonrandomized, open-label study.

Patient receive cyclophosphamide IV over 15-45 minutes, vincristine IV over 3-5 seconds and rituximab IV over 1½-6 hours on day 1, oral prednisone daily on days 1-5, and bortezomib IV over 3-5 seconds on days 1 and 8. Treatment repeats every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity.

Quality of life is assessed at baseline, at the end of each course of treatment, and on day 42 at the post treatment visit.

After completion of study treatment, patients are followed at 3 and 6 weeks and then every 3-6 months thereafter.

PROJECTED ACCRUAL: A total of 90 patients will be accrued for this study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 95
• Est. completion date: January 6, 2012
• Est. primary completion date: April 2011
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 120 Years

Eligibility

DISEASE CHARACTERISTICS:

• Histologically confirmed follicular non-Hodgkin's lymphoma meeting the following criteria:

• Stage III or IV disease

• Grade 1, 2, or 3 disease requiring systemic first-line treatment

• No transformation to diffuse large cell lymphoma

• At least 1 bidimensionally measurable lesion meeting 1 of the following criteria:

• Lymph nodes > 1.5 cm x 1.0 cm by physical exam or CT scan

• Other non-nodal lesion = 1.0 cm x 1.0 cm by MRI or CT scan OR = 1.0 cm x 1.0 cm (e.g., skin lesions or nodules) by physical exam

• Must have a medical indication for treatment, as indicated by 1 of the following:

• Presence of constitutional symptoms that are attributed to lymphoma (e.g., B symptoms, including night sweats, fever, weight loss, fatigue, or pain)

• Lymphadenopathy that requires treatment based on presence of associated symptoms, potential threat to organ function (e.g., ureteric compromise from retroperitoneal disease), or degree of enlargement (i.e., > 5 cm)

• Impairment of normal organ function (e.g., impaired hematopoiesis due to marrow involvement by lymphoma or from splenomegaly and hypersplenism)

• Immune-related complications of lymphoma that require therapy

• Rate of disease progression for which observation is deemed inappropriate

• No history of any other lymphoproliferative disorder or evidence of transformation to an aggressive histology lymphoma

• No known CNS involvement by lymphoma

PATIENT CHARACTERISTICS:

• ECOG performance status 0-2

• Life expectancy = 12 weeks

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

• Platelet count = 75,000/mm^3*

• Absolute neutrophil count = 1,000/mm^3*

• Creatinine = 1.5 times upper limit of normal (ULN)

• Bilirubin = 1.5 times ULN

• AST or ALT = 2.5 times ULN (5 times ULN if liver involvement with lymphoma)

• Able (i.e., sufficiently fluent) and willing to complete the quality of life questionnaires in either English or French

• Inability (illiteracy in English or French, loss of sight, or other equivalent reason) to complete the questionnaires will not make the patient ineligible for the study

• No history of other malignancies, except for the following:

• Adequately treated nonmelanoma skin cancer

• Curatively treated in situ cancer of the cervix

• Ductal carcinoma in situ of the breast (as long as radiation limitation is not exceeded)

• Other solid tumors curatively treated with no evidence of disease for > 5 years

• No history of allergic reactions attributed to compounds containing boron or mannitol

• No history of an unusual or severe allergic reaction to rituximab or similar agent

• No pre-existing neuropathy = grade 2

• No known HIV infection

• No other serious illness or medical condition that would preclude study participation, including any of the following:

• Active, uncontrolled bacterial, fungal, or viral infection

• Significant cardiac dysfunction

• Cardiovascular disease NOTE: *Exceptions will be allowed for values below these thresholds in patients with marrow involvement by lymphoma or lymphoma-related hypersplenism

PRIOR CONCURRENT THERAPY:

• No prior systemic therapy for lymphoma

• No prior bortezomib, cyclophosphamide, or vincristine

• At least 4 weeks since prior radiotherapy that involved = 25% of functioning bone marrow and recovered

• Exceptions may be made for low-dose, nonmyelosuppressive radiotherapy or if the irradiated field is not a significant marrow-bearing area

• At least 2 weeks since prior major surgery

• No other concurrent anticancer therapy, investigational agents, corticosteroids (except for physiologic replacement or antiemesis), cytotoxic chemotherapy, or immunotherapy

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, Follicular
• Lymphoma, Non-Hodgkin

Intervention

Biological:
• rituximab
375mg/m2 day 1

Drug:
• bortezomib
1.3mg/m2 days 1 & 8
• cyclophosphamide
750mg/m2 day 1
• prednisone
40mg/m2 days 1-5
• vincristine sulfate
1.4mg/m2 day 1 (dose capped at 2mg)

Locations

Country	Name	City	State
Canada	Cross Cancer Institute	Edmonton	Alberta
Canada	Hopital Charles LeMoyne	Greenfield Park	Quebec
Canada	QEII Health Sciences Center	Halifax	Nova Scotia
Canada	London Regional Cancer Program	London	Ontario
Canada	Credit Valley Hospital	Mississauga	Ontario
Canada	The Moncton Hospital	Moncton	New Brunswick
Canada	CHUM - Hopital Notre-Dame	Montreal	Quebec
Canada	McGill University - Dept. Oncology	Montreal	Quebec
Canada	CHA-Hopital Du St-Sacrement	Quebec City	Quebec
Canada	Allan Blair Cancer Centre	Regina	Saskatchewan
Canada	Regional Cancer Program of the Hopital Regional	Sudbury	Ontario
Canada	BCCA - Fraser Valley Cancer Centre	Surrey	British Columbia
Canada	Thunder Bay Regional Health Science Centre	Thunder Bay	Ontario
Canada	Humber River Regional Hospital	Toronto	Ontario
Canada	Odette Cancer Centre	Toronto	Ontario
Canada	Univ. Health Network-Princess Margaret Hospital	Toronto	Ontario
Canada	BCCA - Vancouver Cancer Centre	Vancouver	British Columbia
Canada	BCCA - Vancouver Island Cancer Centre	Victoria	British Columbia
Canada	CancerCare Manitoba	Winnipeg	Manitoba

Sponsors (1)

Lead Sponsor	Collaborator
NCIC Clinical Trials Group

Country where clinical trial is conducted

Canada, 

References & Publications (2)

Sehn LH, MacDonald D, Rubin S, Cantin G, Rubinger M, Lemieux B, Basi S, Imrie K, Gascoyne RD, Sussman J, Chen BE, Djurfeldt M, Shepherd L, Couban S, Crump M. Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicula — View Citation

Sehn LH, Macdonald DA, Rubin SH, et al.: Tolerability and efficacy of bortezomib added to CVP-R for previously untreated advanced stage follicular fymphoma: interim analysis of a phase II study by the NCIC Clinical Trials Group. [Abstract] Blood 112 (11):

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Complete response rate		5 years
Primary	Incidence of severe grade 3 or 4 neurotoxicity or neuropathic pain during the first 4 courses of treatment		5 years
Secondary	Overall response rate		5 years
Secondary	Response duration in patients with observed responses		5 years
Secondary	Time to progression		5 years
Secondary	Overall survival		5 years
Secondary	Toxicity		5 years
Secondary	Quality of life		5 years